Natpara Openings







run. Really, RUN. Every issue you can imagine is present and amplified here. Managed care issues? Yep. Inability for patient service center to move product to shipped status? YEP. OVERLY burdensome and ultra conservative compliance issues? Yep. Exec Sales leadership that knows NOTHING about rare disease? Yep. Shire fancy's themselves a rare disease company yet operates like Novartis or Pfizer. This place will implode... Just a matter of when
 






have to agree with above...market size is not even close to what marketing thinks. And we get to have call metric goals for rare disease that one would think are for big pharma. With a little over 50% ship rate it's not real motivating when a new script comes in